Anti-cardiac Troponin I (phospho T143)抗体(ab58546)

概述

  • 产品名称Anti-cardiac Troponin I (phospho T143)抗体
    参阅全部 Cardiac Troponin I 一抗
  • 描述
    兔多克隆抗体to cardiac Troponin I (phospho T143)
  • 特异性Detects endogenous levels of cardiac Troponin I only when phosphorylated at threonine 142.
  • 经测试应用适用于: WB, ELISAmore details
  • 种属反应性
    与反应: Mouse, Rat, Human, Pig
  • 免疫原

    Synthetic phosphopeptide (Human) from around the phosphorylation site of threonine 142 (RPTPLR)

  • 阳性对照
    • Mouse heart extract.

性能

应用

Our Abpromise guarantee covers the use of ab58546 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
WB 1/500 - 1/1000. Detects a band of approximately 30 kDa (predicted molecular weight: 24 kDa).
ELISA 1/10000.

靶标

  • 功能Troponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity.
  • 疾病相关Defects in TNNI3 are the cause of cardiomyopathy familial hypertrophic type 7 (CMH7) [MIM:613690]. Familial hypertrophic cardiomyopathy is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.
    Defects in TNNI3 are the cause of cardiomyopathy familial restrictive type 1 (RCM1) [MIM:115210]. RCM1 is an heart muscle disorder characterized by impaired filling of the ventricles with reduced diastolic volume, in the presence of normal or near normal wall thickness and systolic function.
    Defects in TNNI3 are the cause of cardiomyopathy dilated type 2A (CMD2A) [MIM:611880]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
    Defects in TNNI3 are the cause of cardiomyopathy dilated type 1FF (CMD1FF) [MIM:613286]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
  • 序列相似性Belongs to the troponin I family.
  • Information by UniProt
  • 数据库链接
  • 别名
    • cardiac muscle antibody
    • Cardiac troponin I antibody
    • cardiomyopathy, dilated 2A (autosomal recessive) antibody
    • Cardiomyopathy, familial hypertrophic, 7, included antibody
    • CMD1FF antibody
    • CMD2A antibody
    • CMH7 antibody
    • cTnI antibody
    • Familial hypertrophic cardiomyopathy 7 antibody
    • MGC116817 antibody
    • RCM1 antibody
    • Tn1 antibody
    • Tni antibody
    • TNN I3 antibody
    • TNNC 1 antibody
    • TNNC1 antibody
    • TNNI3 antibody
    • TNNI3_HUMAN antibody
    • Troponin I antibody
    • Troponin I cardiac antibody
    • Troponin I cardiac muscle antibody
    • Troponin I cardiac muscle isoform antibody
    • Troponin I type 3 cardiac antibody
    • troponin I, cardiac 3 antibody
    • TroponinI antibody
    • Ttroponin I type 3 (cardiac) antibody
    see all

Anti-cardiac Troponin I (phospho T143) antibody 图像

  • All lanes : Anti-cardiac Troponin I (phospho T143) antibody (ab58546) at 1/500 dilution

    Lane 1 : Mouse heart extract without immunizing peptide
    Lane 2 : Mouse heart extract with immunizing peptide


    Predicted band size : 24 kDa
    Observed band size : 30 kDa (why is the actual band size different from the predicted?)

Anti-cardiac Troponin I (phospho T143) antibody (ab58546)参考文献

This product has been referenced in:
  • Wu SC  et al. Nuclear localization of a1A-adrenergic receptors is required for signaling in cardiac myocytes: an “inside-out” a1-AR signaling pathway. J Am Heart Assoc 3:e000145 (2014). Read more (PubMed: 24772522) »
  • Boontje NM  et al. Enhanced myofilament responsiveness upon ß-adrenergic stimulation in post-infarct remodeled myocardium. J Mol Cell Cardiol 50:487-99 (2011). WB ; Pig . Read more (PubMed: 21156182) »

See all 3 Publications for this product

Product Wall

Thank you for contacting us.

Unfortunately, at this time we are unable to offer the blocking peptide for ab58546. We apologize for any inconvenience this may cause.

I hope this information is helpful to you. Please do not hesi...

Read More

Thank you for contacting us.

Here is the additional information about blocking peptides that we spoke about. I will let you know if and when we are able to offer a peptide to ab58546.

I hope this information is helpful to you....

Read More
Application Western blot
Sample Rat Cell lysate - whole cell (ventricular myocytes)
Loading amount 40 µg
Specification ventricular myocytes
Treatment + or - ISO
Gel Running Conditions Reduced Denaturing (8-20% gradient SDS PAGE)
Blocking step BSA as blocking agent for 30 minute(s) · Concentration: 3% · Temperature: 22°C
Username

Dr. O Cazorla

Verified customer

提交于 Jul 15 2008

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Western blot
Sample Mouse Cell lysate - whole cell (Cardiac myocytes)
Loading amount 15000 cells
Specification Cardiac myocytes
Treatment 20uM phenylephrine 20 min 37C
Gel Running Conditions Reduced Denaturing (15%)
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 20°C
Username

Abcam user community

Verified customer

提交于 Apr 25 2008

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"